4.8 Article

Mutational Inactivation of STAG2 Causes Aneuploidy in Human Cancer

Journal

SCIENCE
Volume 333, Issue 6045, Pages 1039-1043

Publisher

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1203619

Keywords

-

Funding

  1. NIH [R01CA115699, R21CA143282]
  2. SPORE grant [CA097257]
  3. American Cancer Society [RSG0619101]
  4. National Human Genome Research Institute, NIH

Ask authors/readers for more resources

Most cancer cells are characterized by aneuploidy, an abnormal number of chromosomes. We have identified a clue to the mechanistic origins of aneuploidy through integrative genomic analyses of human tumors. A diverse range of tumor types were found to harbor deletions or inactivating mutations of STAG2, a gene encoding a subunit of the cohesin complex, which regulates the separation of sister chromatids during cell division. Because STAG2 is on the X chromosome, its inactivation requires only a single mutational event. Studying a near-diploid human cell line with a stable karyotype, we found that targeted inactivation of STAG2 led to chromatid cohesion defects and aneuploidy, whereas in two aneuploid human glioblastoma cell lines, targeted correction of the endogenous mutant alleles of STAG2 led to enhanced chromosomal stability. Thus, genetic disruption of cohesin is a cause of aneuploidy in human cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available